Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
MERUS LABS Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MPH HEALTH CARE | 19,250 | -2,28 % | MPH Health Care: Erneut 1,20 Euro Dividende je Aktie | MPH Health Care meldet für das Geschäftsjahr 2024 einen Jahresüberschuss nach IFRS von 32 Millionen Euro ausgewiesen. Damit übertraf MPH den Vorjahreswert von 29,5 Millionen Euro. Das operative Ergebnis... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 7,718 | -1,56 % | EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration | - Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest - - LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of... ► Artikel lesen | |
AMARIN | 10,600 | -5,36 % | XFRA EH3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,430 | +1,42 % | SELLAS Life Sciences Group, Inc.: SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting | - ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer - - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 243,70 | -0,12 % | Citizens JMP behält positive Einschätzung für Madrigal-Aktie bei | ||
CATALYST PHARMACEUTICALS | 22,750 | +0,22 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP... ► Artikel lesen | |
ANI PHARMACEUTICALS | 53,00 | -2,75 % | ANI Pharmaceuticals auf Jefferies-Konferenz: Strategisches Wachstum bei seltenen Krankheiten | ||
DOGECOIN CASH | - | - | Dogecoin Cash, Inc.: MEME Coins Inc. Closes Acquisition of 1 Billion Dogecoin Cash (DOG) Tokens from Tipestry Inc. | Mesquite, June 05, 2025 (GLOBE NEWSWIRE) -- June 5, 2025 - Mesquite, NV - Dogecoin Cash Inc. (OTC: CBDS) announced today that its wholly owned subsidiary, MEME Coins Inc., has successfully closed... ► Artikel lesen | |
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets | Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. | NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and... ► Artikel lesen | |
BLUM HOLDINGS | - | - | Blum Holdings Inc. Reports First Quarter 2025 Financial Results | DOWNEY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the "Company," "Blüm," "Blüm Holdings," "we" or "us"), a California-based publicly traded holding company and cannabis... ► Artikel lesen | |
BMP PHARMA TRADING | 5,500 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr 2024/25 bestätigt | DJ PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr... ► Artikel lesen | |
THERIVA BIOLOGICS | 0,474 | +0,70 % | Theriva Biologics, Inc. - 8-K, Current Report | ||
KAZIA THERAPEUTICS | 5,550 | +2,40 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer | Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve... ► Artikel lesen | |
ALLERGY THERAPEUTICS | 0,072 | -8,86 % | Allergy Therapeutics half-year loss narrows on lower expenses |